Drugs / BP1.3656
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05240560 | Jan 2023 → Feb 2024 | — | Bioprojet | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04727086 | Feb 2021 → Aug 2022 | alcohol dependence | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 2 | NCT03424824 | Jan 2018 → Nov 2021 | alcohol-related disorders | Bioprojet | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP1.3656 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03424824 ↗ |
| Action | Inhibit | “Histamine H3 receptor antagonist/inverse agonist” NCT05240560 ↗ |
| Route | Oral | “Tablet, once daily oral administration at the low dose” NCT03424824 ↗ |